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ABSTRACT : Histamine release caused by drugs and/or their 
solvents is a well known phenomenon. In this study, both in vivo 
(anaesthetized and conscious dog ) and in vitro (isolated rat 
peritoneal, human and guinea-pig lung mast cells) models were 
used. Cremophor E1 and six derivatives of 12-hydroxystearic acid 
were compared for their histamine releasing abilities. Although the 
three types of isolated mast cells responded similarly, histamine 
release being observed with DH (the diester of 12-hydroxystearic 
acid with polyethylene glycol), TN (12-hydroxystearic acid 
polymerized with ethylene oxide) and ME (the monoester of 
12-hydroxystearlc acid esterified with polyethylene glycol), the 
anaesthetized dog exhibited elevated blood histamine levels and 
clinical symptoms after administration of all the solubilizing 
agents, except TN and ME. The reasons for thisdiscrepancy are 
not known. The addition of the drugs (Althesin or propanidid) to 
their solubilizing a ents caused histamine release, which was not 
observed with the solubilizing agent alone. This is the first 
demonstration f an in vitro model, which copies the clinical 
situation, i.e. solvent does nothing but the solvent plus drug 
combination causes histamine release and hence adverse reactions. 
RESUMe : La hb6ration d'histamine, due h des produits anesth6si- 
ques et/ou ~ leurs solvants, est unph6nom6ne bien connu. Deux 
mod61es ont 6t6 utihs6s au cours de cette 6tude : l'un in vivo (chez 
e chlen anesth6si6 ou 6veill6), l'autre in vitro (sur des mastocytes 
xsol6s de p6ritoine de rat, de poumon humain ou de cobaye). Les 
capacit6s histaminolib6ratrices du cr6mophor E1 et de six d6riv6s 
de l'aclde 12-hydroxyst6arique ont 6t6 compar6es. Quoique les 
trois types de mastocytes i ol6s aient r6agi de fa~on analogue, 
l'histaminolib6ration 6tant observ6e avec le DH (diester de l'acide 
12-hydroxyst6afique + poly6thyl~ne glycol), le TN (acide 12- 
hydroxyst6arique polym6ns6 avec de l'oxyde d'6thyl6ne) et le ME
(monoester de l'aclde 12-hydroxyst6arique est6rifi6 avec du 
poly6thyl6ne glycol), le chien anesth6si6 pr6sente un taux 
d'histamine 61ev6 et des sympt6mes chniques apr~s administration 
de tousles agents olvants, sauf le TN et le ME. Les raisons de 
cette dxff6rence ne sont pas connues. L'adjonction d'Alfat6sine ou 
de propanidide aux agents olvants entralne une histaminolib6- 
ration, qui n'6talt pas observ6e avec le solvant seul. Cette 6tude 
est le premier exemple d'un mod61e in vitro, copiant la situation 
clinique : le solvant n'entralne pas de r6action, mals l'adjoncnon 
de prodmt ~t ce dernier provoque une histaminolib6ration et donc 
des effets secondaires. 
Adverse reactions to drugs used during anaesthesia 
and surgery are common. Although reported incidences 
vary considerably, using data obtained from 23 carefully 
controlled clinical trials, the following incidences were 
obtained: all reactions 20-30 %, systemic reactions 
1-5 % and life-threatening reactions 0.1-0.5 % [8]. In 
many cases, these reactions appear to be caused not by 
the drug itself but by the combination of drug and 
solvent. For example, the hypnotic drug Althesin ® was 
found to elevate plasma histamine levels and produce 
tachycardia and hypotension i volunteers but the solvent 
alone, cremophor E l ,  was without adverse effects [3, 
9]. In studies using cats and dogs, however, this solvent 
alone produced elevation of whole blood and plasma 
histamine levels and alterations in haemodynamic para- 
meters [10]. 
In order to reduce the number of adverse reactions, 
two approaches must be followed : 1) the investigation 
of the mechanisms of histamine release caused by the 
solvent or the solvent plus drug combination, 2) the 
development of less toxic solubilizing agents. 
In this study, both in vivo and in vitro techniques have 
been used to investigate the histamine release caused by 
cremophor E1 and related compounds. 
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MODULATION OF HISTAMINE RELEASE BY DRUGS 
MATERIALS AND METHODS 
Anaesthetized og experiments 
Anaesthetized mongrel dogs (both sexes) were prepared as 
previously described [13]. Briefly the dogs were anaesthetized 
with pentobarbitone, two catheters were inserted and 20 min 
allowed to elapse for stabilization. Two blood samples were 
removed before drug administration (to provide basal histamine 
levels) and then 2, 5, 10, 15 and 30 min after drug administration. 
The solubilizing agent was given as an intravenous bolus 
(0.1 ml • kg-~). Histamine was determined in whole blood using 
the combined fluorometric-fluoroenzymatic method [7]. 
Conscious dog experiments 
Beagle dogs (12-18 months old, both sexes) with two indwell- 
ing catheters were used. The drug was administered 
(200 mg • kg -l) via a catheter in the jugular vein; blood sampling 
(via the cephalic vein catheter) was performed at -5 ,  -1 ,  3, 5, 
10, 15 and 30 min after drug injection. Histamine was determined 
in plasma, using the combined fluorometric-fluoroenzymatic assay 
of LORENZ and coworkers [7]. 
Isolated mast cells 
Mast ceils were obtained from human lung [4], guinea-pig lung 
[2] and the peritoneal cavity of the rat [1] by previously described 
methods. Briefly the lung tissue was used as soon as possible after 
organ excision. The tissue was cut into pieces and washed 
thoroughly with Tyrode's-Hepes buffer; it was then chopped into 
1 rfnTl 2 chunks using a Mclllwain tissue chopper and finally 
enzymatically dispersed for 90 mm at 37 °C using collagenase 
type 1 (Sigma) (0.05 % in Tyrode's-Hepes buffer containing 
bovine serum albumin 0.1%). The tissue was then mechanically 
disrupted, filtered through gauze and the cells recovered by 
centrifugation. The cells were then washed twice with Tyrode's- 
Hepes and then used as described below. 
Rat peritoneal mast cells were obtained from female Sprague- 
Dawley rats. These animals were anaesthetized with ether and then 
killed by cervical dislocation and exanguination. Tyrode's-Hepes 
buffer plus heparin was injected into the peritoneal cavity, the 
abdomen was massaged for 90 s and the cells then removed. 
These cells were then washed (twice) and recovered by centrifuga- 
don. The cell suspensions were then used as described below. 
The cell suspensions (to a final volume of 1 ml) were 
prewarmed for 5 min at 37 °C. The drug was added and histamine 
release allowed to proceed for 10 min. The reactions were 
terminated by the addition of ice-cold buffer and the cells and 
supernatants separated by centrifugation. 
Histamine was determined in both portions by the combined 
fluorometric-fluoroenzymatic assay [7]. The results are expressed 
as percentage histamine released, i.e. : % histamine release = 
histamine in supernatantl(histamine in supernatant + cells) x 100. 
The spontaneous histamine release, i.e. the histamine release in 
the absence of any stimulus (ca 5 %), has been subtracted from all 
results in this communication. Positive controls, included in each 
experimental run, used the calcium ionophore A 23187 (10 -6 M) 
and resulted in the release of ca 70 % of the total histamine. 
Matenals 
Cremophor E1 and six derivatives of 12-hydroxystearic acid 
were the seven solubilizing agents tested in this study (generously 
provided by BASF, Ludwigshafen, FRG). The six derivatives of 
12-hydroxystearic a id (12-HSA) were as follows : TN (12-HSA 
polymerized with ethylene oxide; degree of polymerization 15; 
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15 EO), MO (ethoxylated monoglyceride of 12-HSA; 46 EO), ET 
(ethoxylated triglyceride of 12-HSA; 48 EO), DH (diester of 
12-HSA esterified with polyethylene glycol 600; PEG), ED 
(ethoxylated iester of 12-HSA with PEG; 10 EO) and ME 
(monoester of 12-HSA esterified with PEG). 
Preparahons of Althesin and its solubilizer were provided by 
Glaxo; Bayer supplied the samples of propanidid and its 
solubilizer; the calcium ionophore A 23187 was purchased from 
Boehringer. 
RESULTS 
Anaesthetized dog experiments 
In this model, all the solubil izing agents tested, with 
the exception of TN and ME, released clinically 
significant amounts of histamine (> 10 ng • ml -  1 canine 
blood; data not shown). The careful examination of 
clinical symptoms and parameters such as redness, 
oedema, blood pressure changes, etc., confirmed these 
measurements. 
Conscious dog experiments 
TN (200 mg.  kg -1) was administered to the cons- 
cious beagles on four separate occasions (table I). 
Histamine release was reduced on the second applica- 
tion, but higher on the third occasion than on the first. 
The fourth application resulted in either an identical 
release to the first or a markedly higher release. 
Table I. - -  Repeated application of TN in conscious beagles 
Maximum rise in plasma histamine content (ng • m1-1) 
Dog 2801 Dog 4169 
Basal After drug Basal After drug 
Day 1 3.0 96.3 2.4 26.2 
Day 2 0.9 66.3 3.0 4.5 
Day 5 4.4 144.3 0.9 39.3 
Day 8 2.3 96.2 2.3 219.0 
Isolated mast cell experiments 
In contrast o the results obtained with anaesthetized 
dogs, only three solubil izing agents released histamine 
from the three mast cell preparations (human lung, 
guinea-pig lung and rat peritoneal mast cells). The three 
solubilizing agents which released histamine in a 
dose-dependent manner were TN, DH and ME. The 
results obtained with the human lung cells and the rat 
peritoneal mast cells are illustrated in figure 1, those 
obtained with guinea-pig lung cells being omitted for 
clarity. The maximal response to TN was ca  22 % 
(human lung), ca  38 % (guinea-pig tung) and ca  58 % 
(rat peritoneal mast cells). DH produced ca  50 % (rat 
peritoneal mast cells), ca  60 % (human lung) and ca  
18 
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Fig. 1. - -  Histamine release induced by three solubdizing agents 
(TN, DH and ME) from rat peritoneal mast cells (RPMC) and 
human lung ceils. All values are mean -t-SEM, for n = 3-4 
experiments. 
65 % (guinea-pig lung). In all three cell types, ME 
produced near maximal histamine release (70-80 %). 
The action of Althesin and propanidid and their 
solvents was examined using rat peritoneal mast cells 
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Fig. 2. - -  Histamine release induced by Althesin and propanidid 
from rat peritoneal mast cells (top panel) and guinea-pig lung cells 
(bottom panel). All values are mean + SEM, for n = 3-4 
experiments. 
and guinea-pig lung cells (fig. 2). In both cases the 
solvent alone elicited no histamine release, but the drug 
plus solvent combination released histamine. In both 
cases propanidid was much more active. 
DISCUSSION 
There has been much work published on the histamine 
releasing ability of cremophor and its derivatives using 
in vivo models [11-13]. Cremophor El, produced by the 
oxethylation of castor oil at elevated temperatures in an 
alkaline medium, is a mixture of hydrophilic and 
hydrophobic components [12]. In the anaesthetized dog 
model, the hydrophilic components did not release 
histamine. Of the hydrophobic omponents (composed 
of 80 % derivatives of ricinoleic acid, 5 % derivatives 
of oleic acid), only the derivatives of oleic acid released 
histamine [11]. Further experimentation indicated that 
the derivatives of 12-hydroxystearic acid were the least 
dangerous in this test system [13]. In the first part of the 
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study here presented, cremophor E1 and six derivatives 
of 12-hydroxystearic acid were compared using two 
models : the anaesthetized dog and isolated mast cells. 
The results differed markedly in both systems. Only one 
compound (DH) was active in both test systems. Indeed 
the two substances exhibiting no activity in the anaesthe- 
tized dog model (TN, ME) were active in the isolated 
cell systems. It is interesting to note that the response to 
both ME and DH was similar in all three cell types 
examined; only the response to TN exhibited any major 
species difference. In previous studies investigating a
wide range of histamine releasing agents, human and 
guinea-pig lung cells were much less reactive than the 
rat peritoneal mast cells [2, 4]. The solubilizing agents 
have been further examined in rat peritoneal mast cells 
and the results indicated that the response obtained 
occurs via a cytolytic mechanism [6]. However, 
although cremophor E1 and TN have identical tenside 
and micelle-forming properties (Lang, personnal com- 
munication), the responses obtained were very different, 
cremophor being inactive and TN active in the cellular 
systems. 
The results obtained using conscious beagles are the 
first examining the effect of this solubilizing agent on 
non-anaesthetized dogs. The dose used in these experi- 
ments was approximately double that in the anaesthe- 
tized dog studies. Adverse reactions to cremophor E1 
were previously thought o fall into two categories : the 
dog model where the animal reacts on first exposure and 
the pig model where the animal reacts on second 
exposure [5]. In these experiments, although the dogs 
reacted on first exposure and had a reduced reaction on 
second exposure, the third exposure (5 days after the 
first) elicited a much greater response. 
The data presented in the final part of the result 
section demonstrates the first evidence for a model 
which resembles the clinical situation. Mast cells from 
two species (rat and guinea-pig) did not respond to the 
solvent alone but only to the combination of drug plus 
solvent. In both species, the drug propanidid elicited the 
most histamine release. 
In 1984, both Althesin and propanidid were removed 
from the market in many European countries; it might 
therefore be thought that research such as presented in 
this paper is no longer clinically relevant. However, 
many drugs are solubilized with the aid of cremophor, 
including steroid hormones, antibiotics, immunosup- 
pressants and vitamins. In many other preparations, e.g. 
cosmetics, small amounts of cremophor are present. The 
mechanisms of histamine release that are currently being 
investigated include : 
- -A  direct disruptive action on the mast cell 
surface : probably true for DH, TN and ME but not for 
cremophor itself, since this solvent alone does not 
produce histamine release from isolated cells; 
an immunological mechanism involving e.g. com- 
plement activation : a possible mechanism, since WAT- 
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KINS [14] found an involvement of complement in 81% 
of the adverse reactions to Althesin which he had 
investigated; 
- -  a direct but selective action of the drug plus 
solvent combination on the mast cell surface : possible 
and under investigation. 
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Chez des volontalres ains, a 6t6 etudie I'effet d'une 
pr6m6dication de 24 h avec 450 mg de ranitidine et 
1 200 mg de cimetidine, en comparant avec du placebo 
sur les ntveaux plasmatiques de deux benzodiazepines 
administrees oralement en une prise unique : 15 mg de 
m~dazolam (rapport d'extraction hepatique 61eve) ou 
20 mg de temazepam (rapport d'extraction h6patique 
bas). La concentration plasmatique du midazolam est 
significativement superieure apres ranitidine ou cim6tidine 
par comparaison avec le placebo; la concentration plas- 
matique du temazepam n'est nullement affect6e par la 
premedication. La mesure des parametres pharmacocine- 
tiques montre que ranitid~ne t cimetidine augmentent 
d'environ 70 % la biodisponibilite du midazolam, alors 
que celle du temazepam n'est pas modifi6e. 
Ces resultats suggerent que ranitidine et cimetidine 
affectent le fonctionnement hepatique. II etalt d6j~. connu 
que ces deux antagonistes des recepteurs H2 reduisaient 
le d6b~t sanguin h6patique t que la cim6tidine interferait 
avec le metabolisme h6patique des substances par 
I'interm6diaire de sa structure imidazole r~agissant avec 
le cytochrome P45o. Or la ranitidine, ne poss6dant pas 
une telle structure, n'aurait pas d'effet sur le syst~me 
enzymatique microsomal. Ces notions sont actuellement 
controvers6es et il semblerait que la ranitidine puisse se 
lier avec ce systeme enzymatique, xpliquant I'augmenta- 
tlon des concentrations plasmatiques et de la demi-vie 
d'61imination des substances a. m6tabolisme hepatique. 
La pr6m6dication anesthesique a. vis6e antihistami- 
nique par un anti-H2 risque donc de modifier la duree 
d'action des substances & m6tabolisme h6patique utili- 
s6es pour I'anesthesie. 
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